About our Bangalore Facility
Our drug R&D facility based out of Bangalore, India is spread across 17 acres and has a lab space of 1,00,000 sq. ft. and has a legacy of +20 years. This facility has state-of-the-art labs to carry out research and development activities related to small molecules such as peptides, PROTACs, carbohydrates, mPEGs, oligonucleotides, etc.
About our Hyderabad Facility
Our integrated drug R&D center based in Hyderabad, India is spread across 2,60,000 sq. ft. and is capable of handling small and large molecules. The facility has a legacy of +20 years and was audited by FDA in 2017. This facility has state-of-the-art labs to carry out activities related to drug discovery, development and manufacturing.
We have CTO-1, 2 and 3 facilities at our Hyderabad site for manufacturing of APIs and High Potent Active Ingredients (HPAIs).
About our Visakhapatnam Facility
Our CTO-6 and CTO-SEZ manufacturing facilities based in Visakhapatnam, India are spread across 40,07,520 Sq. ft. and 51,83,640 Sq. ft. respectively. We carry out peptide synthesis and manufacturing of APIs (non-sterile), Intermediates and High Potent Active Ingredients (HPAIs) at these facilities. At Visakhapatnam, we have state-of-the-art US FDA and EU-approved pilot & production manufacturing facility, CTO-6 PU-02 for formulations scale-up where we offer clinical & commercial batches. Our Visakhapatnam facility is inspected and approved by major regulatory agencies.
Other Locations
Why Aurigene Services?
18 years of experience
Experience gained from 100+ discovery programmes
World-class infrastructure
Track record of delivering 8+ IND candidates
Flexible working models
Quick turnaround time
Capabilities to apply multiple modalities
Seamless integration capabilities with Biology as well as CDMO services
Integrated project management
Expertise in various therapeutic modalities
Contact Us
Services
Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO) providing end-to-end solutions. With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.